Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214255 | 0.70 | TRPA1 (0.42) | TRPA1 | |
| SCHEMBL6799856 | 0.70 | TRPA1 (0.42) | TRPA1 | |
| SCHEMBL7498164 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL10932771 | 0.65 | TRPA1 (0.38) | TRPA1 | |
| Iodide SCHEMBL7464181 | 0.65 | TRPA1 (0.38) | TRPA1 | |
| SCHEMBL3650633 | 0.65 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL7384086 | 0.64 | TRPA1 (0.46) | TRPA1 | |
| SCHEMBL30816755 | 0.64 | MEN1 (0.33) | TRPA1 | |
| SCHEMBL29901519 | 0.62 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL7350695 | 0.61 | LMNA (0.43) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458677-A1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | Astrazeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| EP-1458672-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR) | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003051826-A1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| WO-2003051822-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| US-20260146032-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2026-05-28 | — | — | US | disclosed |
| US-20260146032-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2026-05-28 | — | — | US | disclosed |
| US-20250333390-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-10-30 | — | — | US | disclosed |
| US-20250333390-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-10-30 | — | — | US | disclosed |
| US-20250326728-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-10-23 | — | — | US | disclosed |
| US-20250326728-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-10-23 | — | — | US | disclosed |
| EP-4347575-B1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-07-23 | — | — | EP | disclosed |
| US-12365658-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2025-07-22 | — | — | US | disclosed |
| WO-2004005247-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004000294-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000790-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000295-A1 | BENZOIC ACID DERIVATIVES AS MODULATORS OF PPAR ALPHA AND GAMMA | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003061663-A1 | USE OF BENZOTHIAZEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT FOR REDUCING CHOLESTEROLOLEMIA | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003051822-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051826-A1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051821-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333390-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | TRPA1 1747/4885 |
| US-20250326728-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | TRPA1 1164/4885 |
| US-12365658-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | TRPA1 1747/4885 |
| US-20260146032-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A2, SLC10A1, SLC5A2 | TRPA1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.